Hepatitis B Exacerbation with a Precore Mutant Virus Following Withdrawal of Lamivudine in a Human Immunodeficiency Virus-infected Patient

Abstract : Chronic active hepatitis B exacerbations have been reported following development of resistance to or withdrawal of lamivudine in HIV-infected patients. A 38-year-old woman with HIV and chronic HBV infections was hospitalized because of acute hepatitis. The occurrence of cytolysis with replication of HBV 2 months after withdrawing lamivudine suggests that our patient experienced a severe reactivation of HBV infection due to the modification of her treatment. Sequencing of the HBV precore region showed the strain to be a mutant. We conclude that lamivudine should not be stopped in HIV- and HBV-infected patients, but could be continued at the dose of 100mg/day as used in isolated HBV infection.
Complete list of metadatas

https://hal.univ-lorraine.fr/hal-02014644
Contributor : Evelyne Schvoerer <>
Submitted on : Monday, February 11, 2019 - 4:36:00 PM
Last modification on : Thursday, July 11, 2019 - 4:04:02 PM

Links full text

Identifiers

Collections

Citation

D. Neau, Evelyne Schvoerer, D. Robert, F. Dubois, H. Dutronc, et al.. Hepatitis B Exacerbation with a Precore Mutant Virus Following Withdrawal of Lamivudine in a Human Immunodeficiency Virus-infected Patient. Journal of Infection, WB Saunders, 2000, 41 (2), pp.192-194. ⟨10.1053/jinf.2000.0724⟩. ⟨hal-02014644⟩

Share

Metrics

Record views

60